| 发明名称 | Liquid pharmaceutical composition comprising nitisinone | ||
| 摘要 | The invention concerns a liquid pharmaceutical formulation suitable for oral administration, comprising a suspension of an effective amount of micronized 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (nitisinone); and citric acid buffer having a pH in the range of 2.5 to 3.5. The formulation is useful in the treatment of disorders and diseases in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) is desirable, e.g. in hereditary tyrosinaemia type I. | ||
| 申请公布号 | US9301932(B2) | 申请公布日期 | 2016.04.05 |
| 申请号 | US201214129090 | 申请日期 | 2012.06.20 |
| 申请人 | SWEDISH ORPHAN BIOVITRUM INTERNATIONAL AB | 发明人 | Svensson Lennart;Sidén Hans |
| 分类号 | A61K31/122;A61K47/12;A61K47/10;A61K47/26;A61K9/10;A61K47/38 | 主分类号 | A61K31/122 |
| 代理机构 | Morrison & Foerster LLP | 代理人 | Morrison & Foerster LLP |
| 主权项 | 1. A liquid pharmaceutical formulation suitable for oral administration, comprising (a) a suspension of 1 to 10 mg/ml of micronized 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (nitisinone); and (b) a citric acid buffer, wherein the liquid pharmaceutical formulation has a pH in the range of 2.5 to 3.5. | ||
| 地址 | Stockholm SE | ||